ArticleCureus2025
The Identification and Challenges of Dopamine Dysregulation Syndrome: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 48-year-old man with a history of opioid use disorder (unmanaged) and presumed Parkinson's disease presented to the emergency department secondary to worsening of his Parkinson's tremors/ambulatory dysfunction. He expressed that he was taking up to 20 doses of his carbidopa/levodopa (25mg-250mg pills for a total of >5g levodopa every day). The patient was admitted for the management of Parkinson's tremors and substance abuse. He was administered carbidopa/levodopa (25mg-250mg) every eight hours. Psychiatry was consulted due to marked functional fluctuations in his presentation and found that he demonstrated positive choreiform movements of the head/neck and upper extremity after taking the carbidopa. The patient's presentation prompted a suspicion of dopamine dysregulation syndrome (DDS). Supporting evidence included that the patient was insistent that the current regimen of carbidopa/levodopa wasn't managing symptoms, and even when the frequency was increased to every six hours, the patient expressed that his symptoms were still present and problematic. The patient stated that if the carbidopa/levodopa dosage wasn't further increased, he would leave the hospital. He ended up leaving against medical advice and was later ultimately re-admitted with the goal of transitioning to a rehabilitation facility for the treatment optimization of his substance use disorder and Parkinson's disease. This case demonstrates the challenges and presentation of DDS. DDS is a disorder marked by compulsive overuse of dopaminergic medication, which frequently occurs in individuals with Parkinson's disease. Additionally, this case reviews diagnostic criteria and moreover summarizes literature supporting methods of clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.